266 related articles for article (PubMed ID: 36191773)
1. Development of amino acid-modified biodegradable lipid nanoparticles for siRNA delivery.
Patel P; Fetse J; Lin CY; Guo Y; Hasan MR; Nakhjiri M; Zhao Z; Jain A; Cheng K
Acta Biomater; 2022 Dec; 154():374-384. PubMed ID: 36191773
[TBL] [Abstract][Full Text] [Related]
2. siRNA Lipid Nanoparticle Potently Silences Clusterin and Delays Progression When Combined with Androgen Receptor Cotargeting in Enzalutamide-Resistant Prostate Cancer.
Yamamoto Y; Lin PJ; Beraldi E; Zhang F; Kawai Y; Leong J; Katsumi H; Fazli L; Fraser R; Cullis PR; Gleave M
Clin Cancer Res; 2015 Nov; 21(21):4845-55. PubMed ID: 26106075
[TBL] [Abstract][Full Text] [Related]
3. Efficient Delivery of Globotriaosylceramide Synthase siRNA using Polyhistidine-Incorporated Lipid Nanoparticles.
Kim IG; Jung WH; You G; Lee H; Shin YJ; Lim SW; Chung BH; Mok H
Macromol Biosci; 2023 Apr; 23(4):e2200423. PubMed ID: 36728673
[TBL] [Abstract][Full Text] [Related]
4. Stabilization of Ostwald ripening in low molecular weight amino lipid nanoparticles for systemic delivery of siRNA therapeutics.
Gindy ME; Feuston B; Glass A; Arrington L; Haas RM; Schariter J; Stirdivant SM
Mol Pharm; 2014 Nov; 11(11):4143-53. PubMed ID: 25317715
[TBL] [Abstract][Full Text] [Related]
5. Light-Activated siRNA Endosomal Release (LASER) by Porphyrin Lipid Nanoparticles.
Mo Y; Cheng MHY; D'Elia A; Doran K; Ding L; Chen J; Cullis PR; Zheng G
ACS Nano; 2023 Mar; 17(5):4688-4703. PubMed ID: 36853331
[TBL] [Abstract][Full Text] [Related]
6. Lipid nanoparticle formulations for optimal RNA-based topical delivery to murine airways.
Tam A; Kulkarni J; An K; Li L; Dorscheid DR; Singhera GK; Bernatchez P; Reid G; Chan K; Witzigmann D; Cullis PR; Sin DD; Lim CJ
Eur J Pharm Sci; 2022 Sep; 176():106234. PubMed ID: 35688311
[TBL] [Abstract][Full Text] [Related]
7. Understanding structure-activity relationships of pH-sensitive cationic lipids facilitates the rational identification of promising lipid nanoparticles for delivering siRNAs in vivo.
Sato Y; Hashiba K; Sasaki K; Maeki M; Tokeshi M; Harashima H
J Control Release; 2019 Feb; 295():140-152. PubMed ID: 30610950
[TBL] [Abstract][Full Text] [Related]
8. Lipid nanoparticles to silence androgen receptor variants for prostate cancer therapy.
Quick J; Santos ND; Cheng MHY; Chander N; Brimacombe CA; Kulkarni J; van der Meel R; Tam YYC; Witzigmann D; Cullis PR
J Control Release; 2022 Sep; 349():174-183. PubMed ID: 35780952
[TBL] [Abstract][Full Text] [Related]
9. Lipid nanoparticle siRNA systems for silencing the androgen receptor in human prostate cancer in vivo.
Lee JB; Zhang K; Tam YY; Tam YK; Belliveau NM; Sung VY; Lin PJ; LeBlanc E; Ciufolini MA; Rennie PS; Cullis PR
Int J Cancer; 2012 Sep; 131(5):E781-90. PubMed ID: 22095615
[TBL] [Abstract][Full Text] [Related]
10. Chemistry of Lipid Nanoparticles for RNA Delivery.
Eygeris Y; Gupta M; Kim J; Sahay G
Acc Chem Res; 2022 Jan; 55(1):2-12. PubMed ID: 34850635
[TBL] [Abstract][Full Text] [Related]
11. Lipid Nanoparticle Formulations for Enhanced Co-delivery of siRNA and mRNA.
Ball RL; Hajj KA; Vizelman J; Bajaj P; Whitehead KA
Nano Lett; 2018 Jun; 18(6):3814-3822. PubMed ID: 29694050
[TBL] [Abstract][Full Text] [Related]
12. Improved Stability of siRNA-Loaded Lipid Nanoparticles Prepared with a PEG-Monoacyl Fatty Acid Facilitates Ligand-Mediated siRNA Delivery.
Sakurai Y; Mizumura W; Ito K; Iwasaki K; Katoh T; Goto Y; Suga H; Harashima H
Mol Pharm; 2020 Apr; 17(4):1397-1404. PubMed ID: 32091909
[TBL] [Abstract][Full Text] [Related]
13. Lipid Nanoparticle Technology for Clinical Translation of siRNA Therapeutics.
Kulkarni JA; Witzigmann D; Chen S; Cullis PR; van der Meel R
Acc Chem Res; 2019 Sep; 52(9):2435-2444. PubMed ID: 31397996
[TBL] [Abstract][Full Text] [Related]
14. Charge-reversible lipid derivative: A novel type of pH-responsive lipid for nanoparticle-mediated siRNA delivery.
Hirai Y; Saeki R; Song F; Koide H; Fukata N; Tomita K; Maeda N; Oku N; Asai T
Int J Pharm; 2020 Jul; 585():119479. PubMed ID: 32473372
[TBL] [Abstract][Full Text] [Related]
15. Cancerous pH-responsive polycarboxybetaine-coated lipid nanoparticle for smart delivery of siRNA against subcutaneous tumor model in mice.
Sung YJ; Guo H; Ghasemizadeh A; Shen X; Chintrakulchai W; Kobayashi M; Toyoda M; Ogi K; Michinishi J; Ohtake T; Matsui M; Honda Y; Nomoto T; Takemoto H; Miura Y; Nishiyama N
Cancer Sci; 2022 Dec; 113(12):4339-4349. PubMed ID: 36047963
[TBL] [Abstract][Full Text] [Related]
16. Lipid Nanoparticle (LNP) Chemistry Can Endow Unique
Johnson LT; Zhang D; Zhou K; Lee SM; Liu S; Dilliard SA; Farbiak L; Chatterjee S; Lin YH; Siegwart DJ
Mol Pharm; 2022 Nov; 19(11):3973-3986. PubMed ID: 36154076
[TBL] [Abstract][Full Text] [Related]
17. Quantitation of physiological and biochemical barriers to siRNA liver delivery via lipid nanoparticle platform.
Xu Y; Ou M; Keough E; Roberts J; Koeplinger K; Lyman M; Fauty S; Carlini E; Stern M; Zhang R; Yeh S; Mahan E; Wang Y; Slaughter D; Gindy M; Raab C; Thompson C; Hochman J
Mol Pharm; 2014 May; 11(5):1424-34. PubMed ID: 24588618
[TBL] [Abstract][Full Text] [Related]
18. [Development of siRNA Delivery Targeting the Tumor Microenvironment with a New Functional Device].
Sakurai Y
Yakugaku Zasshi; 2019; 139(11):1357-1363. PubMed ID: 31685731
[TBL] [Abstract][Full Text] [Related]
19. Influence of particle size on the in vivo potency of lipid nanoparticle formulations of siRNA.
Chen S; Tam YYC; Lin PJC; Sung MMH; Tam YK; Cullis PR
J Control Release; 2016 Aug; 235():236-244. PubMed ID: 27238441
[TBL] [Abstract][Full Text] [Related]
20. Development of EphA2 siRNA-loaded lipid nanoparticles and combination with a small-molecule histone demethylase inhibitor in prostate cancer cells and tumor spheroids.
Oner E; Kotmakci M; Baird AM; Gray SG; Debelec Butuner B; Bozkurt E; Kantarci AG; Finn SP
J Nanobiotechnology; 2021 Mar; 19(1):71. PubMed ID: 33685469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
